Amicus Therapeut Stock Price, News & Analysis

Amicus Therapeutics (FOLD) reported Galafold revenue of approximately $261 million for 2020, exceeding guidance of $250-$260 million and reflecting a 43% year-over-year growth. The company completed the last patient visit in the AT-GAA Phase 3 PROPEL study, with data expected in 1Q2021. Amicus anticipates Galafold revenue of at least $300 million for 2021 and plans to submit the BLA for AT-GAA in the first half of the year. With a strong cash position, the company aims for self-sustainability without further dilutive financing.

Amicus Therapeutics (Nasdaq: FOLD) announced that its CEO, John F. Crowley, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 8:20 a.m. ET. A live audio webcast of the presentation will be available on the company’s investor website.

Amicus Therapeutics focuses on developing innovative therapies for rare metabolic diseases, driven by a commitment to patient care. For insights, visit the company's website.

Amicus Therapeutics (Nasdaq: FOLD) has been awarded the Great Place to Work-Certified™ status for 2020, recognizing its positive workplace culture as rated by employees. The certification is based on validated feedback and highlights Amicus's commitment to employee experience and corporate culture. Chief People Officer David Clark emphasized the company's focus on diverse backgrounds and employee engagement to foster talent and innovation. This accolade indicates a strong alignment between workplace culture and business performance, which may positively influence investor confidence.

Amicus Therapeutics (Nasdaq: FOLD) has appointed Michael A. Kelly to its Board of Directors, bringing over 20 years of experience in the life sciences sector. Kelly, who founded Sentry Hill Partners, previously held senior positions at Amgen, including CFO. CEO John Crowley highlighted Kelly's expertise as vital for the company's growth, particularly in navigating the biotechnology landscape focused on rare diseases. Kelly expressed enthusiasm to contribute to Amicus's mission during a pivotal growth phase.

Amicus Therapeutics (Nasdaq: FOLD) announced the initiation of its rolling Biologics License Application (BLA) submission to the FDA for AT-GAA, a therapy for late onset Pompe disease (LOPD). This rolling submission allows the company to submit application sections as they are completed. The FDA granted Breakthrough Therapy Designation for AT-GAA based on positive Phase 1/2 trial results. Top-line data from the global Phase 3 PROPEL study is expected in 1Q2021, with all manufacturing activities completed successfully.

Amicus Therapeutics (Nasdaq: FOLD) will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference on December 1, 2020, at 2:15 p.m. E.T. Interested parties can listen to the event through a live audio webcast available on the company’s corporate website. Amicus is dedicated to developing innovative treatments for rare metabolic diseases, reflecting its commitment to patient care and a robust pipeline of novel therapies. For more details, visit their website.

Amicus Therapeutics (Nasdaq: FOLD) reported 3Q20 revenue of $67.4 million, a 38% increase from $48.8 million in 3Q19, affirming its full-year revenue guidance of $250 million to $260 million. The revenue growth is mainly driven by strong demand for Galafold, with compliance rates exceeding 90%. The PROPEL study for AT-GAA is on track for data release in 1Q21, while positive CLN6 gene therapy data has been presented. The company maintains a strong cash position of $509.1 million, supporting ongoing operations through to self-sustainability.

Amicus Therapeutics (Nasdaq: FOLD) announced that CEO John F. Crowley will speak at the Credit Suisse 29th Annual Virtual Healthcare Conference on November 9, 2020, at 8:00 a.m. ET. The event will provide insights into the company's focus on rare metabolic diseases.

Investors can access a live audio webcast of the presentation via the Amicus Therapeutics website. The company is dedicated to developing high-quality medicines for those affected by rare diseases.

Amicus Therapeutics (Nasdaq: FOLD) will host a conference call and live audio webcast on November 5, 2020, at 8:30 a.m. ET to discuss its third-quarter financial results for the period ending September 30, 2020. Participants can join the call by dialing specific numbers and using the conference ID 7788189. A live audio webcast will also be available on the company's investor website. A replay of the call will be accessible for seven days post-event. Amicus Therapeutics focuses on developing innovative medicines for rare metabolic diseases.